Page last updated: 2024-08-24

glucose, (beta-d)-isomer and Hematologic Malignancies

glucose, (beta-d)-isomer has been researched along with Hematologic Malignancies in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, G; Guo, Q; Liu, J; Sun, H; Wu, Y; Xu, Y1
Alvarado, Y; Borthakur, G; Bueso-Ramos, C; Cortes, J; Estrov, Z; Faderl, S; Giles, F; Ivy, P; Nebiyou Bekele, B; Ravandi-Kashani, F1

Reviews

1 review(s) available for glucose, (beta-d)-isomer and Hematologic Malignancies

ArticleYear
Natural products against hematological malignancies and identification of their targets.
    Science China. Life sciences, 2015, Volume: 58, Issue:12

    Topics: Biological Products; Diterpenes, Kaurane; Flavanones; Glucosides; Hematologic Neoplasms; Humans; Molecular Structure; Molecular Targeted Therapy; Phytotherapy; Xanthones

2015

Trials

1 trial(s) available for glucose, (beta-d)-isomer and Hematologic Malignancies

ArticleYear
Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies.
    Cancer, 2008, Jul-15, Volume: 113, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Biopsy; Bone Marrow; Carbazoles; Dose-Response Relationship, Drug; Female; Glucosides; Hematologic Neoplasms; Humans; Male; Middle Aged; Virus Diseases

2008